The colony-stimulating factor-1 (CSF-1) receptor is a protein ± tyrosine kinase that regulates the proliferation and dierentiation of monocyte and macrophage precursors. Binding of CSF-1 to its receptor results in activation of the kinase domain and autophosphorylation on a number of tyrosine residues. Phosphorylated tyrosine residues function as binding sites for SH2 domain-containing signaling proteins. It is known that activated receptors are internalized and degraded, but the mechanics of this process remain largely unknown. Recently, evidence has started to emerge that the ubiquitin ± protein ligase c-Cbl is involved in CSF-1 receptor degradation. In addition, there is evidence that the CSF-1 receptor carboxy-terminus is involved in down regulation of the receptor. Here we show that the c-Cbl tyrosine kinase-binding (TKB) domain binds in vitro and in vivo to the CSF-1 receptor. Binding is dependent on the receptor's protein ± kinase activity. Deletion of the carboxy-terminus or mutation of Tyr 973 blocks binding. We further provide evidence that the CSF-1 receptor's carboxy-terminus is a substrate for autophosphorylation. Our observations are consistent with a model in which receptor autophosphorylation at Tyr 973 creates a binding site for c-Cbl. Association of c-Cbl with the receptor leads to ubiquitination, followed by receptor degradation.
Introduction
Receptor protein ± tyrosine kinases (RPTKs) are integral membrane proteins that regulate a variety of cellular processes in response to speci®c extracellular messenger molecules. Ligand binding results in receptor dimerization followed by autophosphorylation. Autophosphorylation sites regulate kinase activity and act as binding sites for cytoplasmic signaling molecules.
The interaction of cytoplasmic signaling proteins with the activated receptor is usually mediated by Srchomology 2 (SH2) or phosphotyrosine-binding (PTB) domains (Pawson, 1995; Schlessinger, 2000; van der Geer et al., 1994) . Signaling proteins are activated directly or indirectly as a consequence of their interaction with the receptor.
The colony-stimulating factor-1 (CSF-1) receptor is a protein ± tyrosine kinase that regulates the proliferation and dierentiation of monocyte and macrophage precursors (Bourette and Rohrschneider, 2000; Stanley et al., 1983) . Inappropriate activation of the CSF-1 receptor has been implicated in a variety of malignancies (Kacinski, 1995 (Kacinski, , 1997 . Upon activation, the CSF-1 receptor autophosphorylates on several cytoplasmic tyrosine residues, including tyrosines 697, 706, 721 and 807 (Reedijk et al., 1992; Tapley et al., 1990; van der Geer and Hunter, 1990) . Tyrosines 697 and 721 form binding sites for the adaptor protein Grb2 and the p85 subunit of phosphatidylinositol 3'-kinase (PI 3'-Kinase), respectively (Lioubin et al., 1994; Reedijk et al., 1992; van der Geer and Hunter, 1993) . Tyr 697 also binds the novel hematopoietic adaptor protein Mona, and Tyr 721 may function as a binding site for PLCg2 (Bourette et al., 1997 (Bourette et al., , 1998 . There is some evidence that Tyr 706 forms a binding site for members of the STAT family of transcription factors (Novak et al., 1996) . Tyr 807 is conserved in most protein ± tyrosine kinases and its phosphorylation results in an increase in kinase activity (Roussel et al., 1990; . Tyr 559 has been shown to act as a binding site for members of the Src family of protein ± tyrosine kinases (Alonso et al., 1995; Courtneidge et al., 1993) .
The gene encoding the CSF-1 receptor was ®rst identi®ed based on its homology with v-fms, the transforming gene of the SM-strain of feline sarcoma virus (Heisterkamp et al., 1983; Sherr et al., 1985) . Expression of the v-Fms protein leads to morphological transformation in vitro and the formation of tumors in vivo (Donner et al., 1982; Roussel et al., 1984) . Substitution of Leu 301 and Ala 374 with serine and deletion of the 50 carboxy-terminal amino acids are both essential for complete activation of the transforming potential of the CSF-1 receptor (Woolford et al., 1988) . This suggests the carboxy-terminus may play a role in negative regulation of CSF-1 receptor signaling.
Recently, the ubiquitin ± protein ligase c-Cbl was identi®ed as a negative regulator of receptor protein ± tyrosine kinase signaling. c-Cbl was originally identi®ed as a mammalian homologue of Sli-1, a negative regulator of EGF receptor signaling in C. elegans (Yoon et al., 1995) . c-Cbl is a 120 kDa cytosolic protein comprised of an amino-terminal tyrosine kinase binding (TKB) domain, a ring-®nger, a proline-rich region and a carboxy-terminus containing several tyrosine phosphorylation sites (Figure 1 ). The TKB domain, which is comprised of a four helix bundle, an EF hand and a variant SH2 domain, was found to bind to activated protein ± tyrosine kinases (Joazeiro et al., 1999; Meng et al., 1999; Thien and Langdon, 2001; Zheng et al., 2000) . The ring-®nger is capable of binding ubiquitin-conjugating enzymes (Joazeiro et al., 1999; Zheng et al., 2000) . The proline ± rich region contains binding sites for several Src-homology 3 (SH3) domain-containing proteins, while phosphorylation of tyrosine residues in the carboxy-terminus activates the potential to bind SH2 domain-containing proteins (Blake et al., 1991; Feshchenko et al., 1998) . Thus, c-Cbl binds to activated protein ± tyrosine kinases and has the potential to recruit other proteins to the complex.
The current model suggests that c-Cbl performs multiple functions downstream of RPTKs. It binds to activated receptors via its TKB domain and recruits, through its ring-®nger, ubiquitin-conjugating enzymes (Joazeiro et al., 1999; Yokouchi et al., 1999; Zheng et al., 2000) . Recruitment of these enzymes results in receptor ubiquitination and targeting of the receptors for degradation Waterman et al., 1999) . It is well documented that c-Cbl becomes tyrosine phosphorylated upon its association with activated receptors. This has led to the idea that Cbl may provide the activated receptor with additional binding sites for SH2 domain-containing signaling proteins. (GarciaGuzman et al., 2000; Hunter et al., 1999; Thien and Langdon, 2001) . c-Cbl is thus an active participant in both signaling and signal termination. v-Cbl is the transforming gene present in the Cas NS-1 retrovirus that induces B-cell lymphomas in mice. This oncogenic version of the Cbl protein is comprised of the amino-terminal 355 amino acids of c-Cbl. It contains only the TKB domain and lacks the ability to bind ubiquitin-conjugating enzymes (Blake et al., 1991) . v-Cbl is thought to transform cells by competing with full-length c-Cbl for phosphotyrosine-based binding sites on activated receptors. By preventing c-Cbl from interacting with activated receptors, v-Cbl blocks ubiquitination and targeting of the activated receptors for degradation (Bonita et al., 1997; Miyake et al., 1997) . This results in prolonged signaling by activated receptors and, subsequently, uncontrolled cell division.
c-Cbl binds to the receptors for platelet-derived growth factor (PDGF) and epidermal growth factor (EGF). Binding depends on receptor activation and results in their ubiquitination and degradation (Joazeiro et al., 1999; Levkowitz et al., 1998; Miyake et al., 1998 Miyake et al., , 1999 . There is evidence that c-Cbl is also involved in CSF-1 receptor degradation. c-Cbl is tyrosine phosphorylated and becomes associated with the plasma membrane upon CSF-1 receptor activation (Wang et al., 1996 . CSF-1 receptors in c-Cbl de®cient macrophages are ubiquitinated to a lesser extent and are internalized at a lower rate (Lee et al., 1999) . These results support a model in which c-Cbl plays a role in negatively regulating CSF-1 receptor signaling.
In this study, we have demonstrated the ability of the c-Cbl TKB domain to bind to activated CSF-1 receptors in vivo and in vitro. Binding is dependent on the receptor's kinase activity and can be blocked by deletion of the carboxy-terminal 50 amino acids. This led to the identi®cation of Tyr 973 as the binding site for c-Cbl. Phosphopeptide mapping of in vitro phosphorylated receptors con®rmed that the CSF-1 receptor is capable of autophosphorylation at Tyr 973. These data explain the observation that deletion of the carboxy-terminus contributes to the transforming potential of v-fms. Figure 1 Cbl proteins used in this study. c-Cbl is comprised of 906 amino acids and contains an amino-terminal tyrosine-kinase binding (TKB) domain, a ring ®nger (RF) domain, a proline-rich region, and a carboxy-terminus containing a number of tyrosine phosphorylation sites. The ring ®nger domain is essential for the recruitment of ubiquitin-conjugating enzymes, the proline-rich region may bind to SH3 domain-containing proteins, and the carboxy-terminus is thought to provide binding sites for SH2 domaincontaining proteins. A GST-fusion protein is used to study binding to the CSF-1 receptor in vitro. Mutation of glycine 306 to glutamate inactivates the TKB domain. An HA-TKB domain fusion protein is used to study the interaction with the CSF-1 receptor in cells c-Cbl binds the CSF-1 receptor's carboxy-terminus K Wilhelmsen et al
Results
The c-Cbl protein is thought to be involved in targeting activated receptor protein ± tyrosine kinases, including the CSF-1 receptor, for degradation. This prompted us to investigate the interaction between c-Cbl and the CSF-1 receptor. To test whether c-Cbl can bind to the CSF-1 receptor in vitro we used a GST-c-Cbl TKB domain fusion-protein (GST-TKB, Figure 1 ). Lysates of control and CSF-1 stimulated p388D1 macrophages were incubated with the GST-TKB fusion-protein immobilized on glutathione-agarose beads. Bound proteins were resolved by SDS ± PAGE and analysed by anti-P.Tyr and anti-CSF-1 receptor immunoblotting. A mutant fusion-protein in which glycine 306 had been replaced with glutamic acid (Glu 306) was used as a negative control (Figure 1 ). The glycine to glutamic acid mutation, which was originally identi®ed in C. elegans, destroys the ability of c-Cbl to bind to phosphorylated tyrosine residues Yoon et al., 1995) . Our results show that the c-Cbl TKB domain can bind to CSF-1 receptors present in lysates of macrophages, but only if the cells were lysed following stimulation with CSF-1 (Figure 2a ). In contrast, the inactive mutant GST-TKB domain did not bind to CSF-1 receptors (Figure 2a ). These data show that the c-Cbl TKB domain binds speci®cally to activated CSF-1 receptors. Identi®cation of the c-Cbl binding site on the CSF-1 receptor requires testing of mutant receptors for their ability to bind to the TKB domain. Mutant receptors can be expressed eciently by transient transfection in 293T cells, which do not express endogenous CSF-1 receptors. Lysates of control and CSF-1 stimulated cells, transiently expressing wild-type and mutant receptors, were incubated with wild-type and mutant GST-TKB fusion-protein immobilized on glutathioneagarose beads. The bound proteins were then analysed for the presence of the CSF-1 receptor. CSF-1 receptor immunoprecipitates were analysed in parallel. The wild-type TKB domain bound speci®cally to the activated CSF-1 receptors present in the lysates of 293T cells, while the mutant TKB domain did not (Figure 2b ). To test whether the association with the CSF-1 receptor was dependent on autophosphorylation, we expressed a mutant receptor in which Lys 614 had been mutated to Met. Lys 614 is conserved in all protein ± tyrosine kinases and is necessary for catalytic activity (Hanks et al., 1988) . Mutant receptors were unable to bind to the GST-TKB fusion-protein ( Figure  2c ). These data show that the c-Cbl TKB domain binds speci®cally to activated CSF-1 receptors expressed in 293T cells. Binding depends on the receptor's ability to autophosphorylate.
To test whether c-Cbl can bind to the CSF-1 receptor in cells, we ®rst tried to show the association between c-Cbl and the CSF-1 receptor using a fulllength c-Cbl protein and were unable to see an association (data not shown). During these experiments we noticed that expression of the c-Cbl protein in the presence of the CSF-1 receptor resulted in a rapid downregulation of full-length c-Cbl (data not shown). This observation is consistent with results obtained by Stanley and co-workers (Wang et al., 1996) . We reasoned that the inability to co-precipitate the CSF-1 receptor with c-Cbl resulted from the low steady state c-Cbl levels observed in the presence of the CSF-1 receptor. In an attempt to avoid this problem we made a construct that drives the expression of an HA-tagged c-Cbl TKB domain (HA-TKB, Figure 1 ). This protein, lacking a ring ®nger, should be able to bind to the receptor without promoting any ubiquitination and downregulation.
To test whether the c-Cbl TKB domain can bind to the activated CSF-1 receptor in vivo, we expressed both the CSF-1 receptor and HA-TKB by transient transfection in 293T cells. Cells expressing the inactive mutant TKB domain or cells lacking the CSF-1 receptor were included as controls. Receptor levels and receptor autophosphorylation in response to CSF-1 were unaected by the presence of the wildtype or mutant TKB domain ( Figure 3 ). TKB domains were expressed at similar levels ( Figure 3 ). HA immunoprecipitates were probed for the presence of the CSF-1 receptor by anti-P.Tyr immunoblotting ( Figure 3 , top panel). CSF-1 receptor immunoprecipitates were analysed in parallel. This experiment showed that the c-Cbl TKB domain binds to activated CSF-1 receptors in vivo. The inactive mutant c-Cbl TKB failed to bind to the receptor. Our data show that c-Cbl can bind stably to the activated CSF-1 receptor.
Four CSF-1 receptor autophosphorylation sites (Tyr 697, Tyr 706, Tyr 721 and Tyr 807) have been identi®ed previously. To ®nd out whether any of these sites acts as a c-Cbl binding site, phosphorylation site mutants were expressed in 293T cells and tested for their ability to bind to the GST-TKB fusion-protein in vitro. Cells expressing the wild-type receptors and cells lacking CSF-1 receptors were included as controls. All receptors were expressed at similar levels and most phosphorylation site mutants were unaected in their ability to autophosphorylate ( Figure 4 ). As expected, we observed a reduced ability to autophosphorylate in the Phe 807 mutant receptor ( Figure 4 ) (van der Geer and Hunter, 1991). Our results show that none of the receptors with mutations at known autophosphorylation sites appeared to be aected in their ability to bind to the c-Cbl TKB domain in vitro (Figure 4 ). This indicates that none of the known CSF-1 receptor autophosphorylation sites are essential for the interaction between the receptor and c-Cbl.
Analysis of CSF-1 receptor and v-Fms chimera suggested that the carboxy-terminus acts as a negative regulator of CSF-1 receptor signaling (Browning et al., 1986; Woolford et al., 1988) . To test whether the CSF-1 receptor carboxy-terminus contains the c-Cbl-binding site, we generated a mutant receptor lacking the carboxy-terminal 50 amino acids (D50 CT). This mutant was expressed in 293T cells and was tested for its ability to bind to the GST-TKB fusion-protein in vitro. Wild-type and kinase inactive receptors were analysed in parallel ( Figure 5 ). Control experiments show that the D50 CT mutant was expressed at levels comparable to the wild-type receptor and that it was unaected in its ability to autophosphorylate ( Figure 5 , bottom two panels). Our data show that the truncated receptor has lost the ability to bind to the GST-TKB fusion protein. This suggests that the c-Cbl-binding site is contained within the carboxy-terminal 50 amino acids of the CSF-1 receptor.
To narrow down the region necessary for c-Cbl binding, we generated a series of carboxy-terminal truncations of the CSF-1 receptor lacking either 50, 40, 30, 20 or 10 amino acid residues. None of these receptors were able to bind to the GST-TKB fusionprotein (data not shown). This suggests that the c-Cbl binding site is contained, at least in part, within the carboxy-terminal 10 amino acids of the CSF-1 receptor.
Only one tyrosine residue, at position 973, is present within the carboxy-terminal 10 amino acids of the CSF-1 receptor. Tyrosine 973 was mutated to phenylalanine (Phe 973), and this mutant receptor was expressed in 293T cells and tested for its ability to bind to the GST-TKB fusion-protein in vitro. Wildtype receptors, receptors lacking the carboxy-terminal 10 amino acids (D10 CT) and receptors with an inactive kinase domain (Met 614) were analysed in parallel ( Figure 6 ). The D10 CT and the Phe 973 receptor mutants were expressed at levels comparable to the wild-type receptor and were unaected in their ability to autophosphorylate ( Figure 6 ). Our data show that both the D10 CT receptor and the Phe 973 mutant receptor were strongly aected in their ability to bind to the c-Cbl TKB domain in vitro. This suggests that Tyr 973 acts as a major c-Cbl binding site in vitro.
To investigate the contribution of Tyr 973 to c-Cbl binding in vivo, we expressed the mutant receptor together with the HA-TKB in 293T cells. The wild-type receptor and the receptor mutant that lacks kinase activity (Met 614) were analysed in parallel. Receptors were expressed at similar levels and the wild-type and Phe 973 mutant receptor showed similar levels of autophosphorylation in response to CSF-1 (Figure 7) . The HA-TKB was expressed at similar levels in all cells (Figure 7) . The wild-type receptor and the Phe 973 mutant receptor showed similar levels of autophosphorylation in response to CSF-1. To test the ability of these receptors to bind to c-Cbl, HA-immunoprecipitates of control and CSF-1 stimulated cells were probed for the presence of the CSF-1 receptor. Our data show that wild-type receptors were present in HA immunoprecipitates while the Phe 973 receptors were not (Figure 7 ). These observations indicate that Tyr 973, four residues from the carboxyl end of the CSF-1 receptor, is essential for the interaction between the CSF-1 receptor and the c-Cbl TKB domain in cells. or CSF-1 stimulated (lanes 2, 4, 8 and 10) p388D1 macrophages were incubated with mutant (lanes 1, 2, 7 and 8) or wild-type (lanes 3, 4, 9 and 10) GST-TKB fusion-proteins immobilized on glutathione-agarose. Bound proteins were analysed by anti-P.Tyr (lanes 1 ± 6) and anti-CSF-1 receptor (lanes 7 ± 10) immunoblotting. CSF-1 receptor immunoprecipitates from control (lane 5) and CSF-1 stimulated (lane 6) cells were analysed in parallel. (b) 293T cells were transfected with a CSF-1 receptor expression construct (lanes 1 ± 4, 6 and 7) or with a control plasmid (lanes 5 and 8). Lysates of control (lanes 1 and 3) and CSF-1 stimulated (lanes 2, 4 and 5) cells were incubated with the inactive mutant (lanes 1 and 2) or the wild-type (lanes 3 ± 5) GST-TKB fusionprotein immobilized on glutathione-agarose. Bound proteins were analysed by anti-P.Tyr (top panel) and anti-CSF-1 receptor (bottom panel) immunoblotting. CSF-1 receptor immunoprecipitates from control (lane 6) and CSF-1 stimulated (lanes 7 and 8) cells were analysed in parallel. (c) 293T cells were transfected with an expression construct containing the kinase inactive mutant CSF-1 receptor (Met 614) (lanes 1 ± 4, 6 and 7) or a control plasmid (lanes 5 and 8). Lysates of control (lanes 1 and 3) or CSF-1 stimulated (lanes 2, 4 and 5) cells were incubated with the inactive (lanes 1 and 2) or the wild-type (lanes 3 ± 5) GST-TKB fusion-protein immobilized on glutathione-agarose. Bound proteins were analysed by anti-CSF-1 receptor immunoblotting. CSF-1 receptor immunoprecipitates from control (lane 6) and CSF-1 stimulated (lanes 7 and 8) cells were analysed in parallel c-Cbl binds the CSF-1 receptor's carboxy-terminus K Wilhelmsen et al
Previous work has shown that the c-Cbl TKB domain binds directly to phosphorylated tyrosine residues on activated receptors (Joazeiro et al., 1999; Levkowitz et al., 1999) . Our observations suggest that, in order to function as a c-Cbl binding site, Tyr 973 is likely to act as a target for autophosphorylation. To Figure 3 The c-Cbl TKB domain binds to activated CSF-1 receptors in vivo. 293T cells were transiently transfected with a CSF-1 receptor expression construct (lanes 1 ± 5 and 8) or a control plasmid (lanes 6, 7 and 9) and expression constructs for wild-type (lanes 4 ± 6) or inactive mutant (lanes 2 and 3) HAtagged c-Cbl TKB domain. HA immunoprecipitates of control (lanes 2 and 4) and CSF-1 stimulated (lanes 1, 3 and 5 ± 7) cells were probed for the presence of the CSF-1 receptor and the HA-TKB by anti-P.Tyr (top panel) and anti-HA (second panel from the top) immunoblotting, respectively. CSF-1 receptor immunoprecipitates from CSF-1 stimulated (lanes 8 and 9) cells were analysed in parallel. CSF-1 receptor immunoprecipitates from samples 1 ± 7 were analysed by anti-P.Tyr (third panel from the top) and anti-CSF-1 receptor immunoblotting (bottom panel) Figure 4 CSF-1 receptors with phenylalanine replacements at the known tyrosine phosphorylation sites still bind the c-Cbl TKB domain in vitro. 293T cells were transiently transfected with expression constructs containing the wild-type (lanes 1 and 2) , the Phe 697 (lanes 3 and 4) , the Phe 706 (lanes 5 and 6), the Phe 721 (lanes 7 and 8) and the Phe 807 (lanes 9 and 10) CSF-1 receptor cDNA or a control plasmid (lane 11). Lysates of control (lanes 1, 3, 5, 7 and 9) and CSF-1 stimulated (lanes 2, 4, 6, 8, 10 and 11) cells were incubated with GST-TKB fusion-proteins immobilized on glutathione-agarose. Bound proteins were analysed by anti-P.Tyr immunoblotting (top panel). CSF-1 receptor immunoprecipitates from samples 1 ± 11 were analysed by anti-P.Tyr (middle panel) and anti-CSF-1 receptor (bottom panel) immunoblotting 293T cells were transiently transfected with expression constructs for the wild-type CSF-1 receptor (lanes 1 and 2) , the kinase inactive CSF-1 receptor (lanes 3 and 4) , a mutant CSF-1 receptor lacking the carboxy-terminal 10 amino acids (lanes 5 and 6) and the Phe 973 CSF-1 receptor (lanes 7 and 8) or a control plasmid (lane 9). Lysates of control (lanes 1, 3, 5 and 7) or CSF-1 stimulated (lanes 2, 4, 6, 8 and 9) cells were incubated with the GST-TKB fusion-protein immobilized on glutathione-agarose. Bound proteins were detected by anti-P.Tyr immunoblotting (top panel). CSF-1 receptor immunoprecipitates from samples 1 ± 9 were analysed in parallel by anti-P.Tyr (middle panel) and anti-CSF-1 receptor immunoblotting (bottom panel) Figure 8a . To ®nd out whether any of the phosphopeptides shown on this map are derived from the carboxy-terminus we incubated the peptide mixture with an antibody that was raised against the carboxy-terminal 20 amino acids and immobilized on protein A-agarose beads. Bound peptides were eluted at pH 1.9 and resolved by electrophoresis and chromatography on a TLC plate (Figure 8b ). Our data show that a series of three or more phosphopeptides present on the CSF-1 receptor phosphopeptide map are derived from the carboxyterminus (Figures 8b and 9a ). To con®rm this result, we generated a GST fusion-protein containing the carboxy-terminal 63 amino acids of the receptor. The puri®ed fusion-protein was phosphorylated in vitro by incubation with immunoprecipitated CSF-1 receptors in the presence of [g 32 P]-ATP. The radiolabeled protein was resolved from contaminants by SDS ± PAGE and subjected to tryptic phosphopeptide mapping. Our data show that this fusion-protein gave rise to a series of phosphopeptides similar to those present in the receptor digest (Figure 8c ). The appearance of multiple spots on a phosphopeptide map representing a single tryptic peptide can be caused by separation of phosphorylation state isomers. Phosphorylation state isomers are phosphopeptides derived from the same peptide that dier in the number of phosphorylated Receptors were resolved from contaminants by SDS ± PAGE, digested with trypsin, and the resultant peptide mixture was resolved by electrophoresis and chromatography in two dimensions on a TLC plate. Phosphate-labeled peptides were detected by autoradiography. (b) A tryptic digest of in vitro autophosphorylated CSF-1 receptors was incubated with antibodies, raised against the CSF-1 receptor carboxy-terminus, immobilized on protein A-agarose beads. Bound peptides were eluted at pH 1.9 and resolved and detected as described in (a). (c) A GST-fusion protein containing the CSF-1 receptor carboxyterminal 63 amino acids was labeled in vitro by incubation with the CSF-1 receptor in the presence of g 32 P-ATP. The labeled fusion protein was resolved from contaminants and analysed by tryptic phosphopeptide-mapping as described in (a). (d) Schematic CSF-1 receptor tryptic phosphopeptide map showing the tryptic phosphopeptides derived from the known CSF-1 receptor autophosphorylation sites. Tryptic phosphopeptides with the same tyrosine phosphorylation site are represented by the same shading pattern. Horizontally hatched spots represent unmapped tyrosine phosphorylation sites Figure 7 Tyrosine 973 in the CSF-1 receptor carboxy-terminus is essential for association with the c-Cbl TKB domain in cells. 293T cells were transiently transfected with expression constructs for the wild-type CSF-1 receptor (lanes 1, 2 and 8), the Met 614 mutant CSF-1 receptor (lanes 3 and 4) and the Phe 973 mutant CSF-1 receptor (lanes 5 and 6) or a control plasmid (lanes 7 and 9) and an expression construct for the HA-c-Cbl TKB domain (lanes 1 ± 7). HA immunoprecipitates from control (lanes 1, 3 and 5) or CSF-1 stimulated (lanes 2, 4 and 6 ± 9) cells were analysed by anti-P.Tyr (top panel) and anti-HA immunoblotting (second panel from the top). CSF-1 receptor immunoprecipitates from samples 1 ± 9 were analysed in parallel by anti-P.Tyr (second panel from the bottom) and anti-CSF-1 receptor (bottom panel) immunoblotting c-Cbl binds the CSF-1 receptor's carboxy-terminus K Wilhelmsen et al residues (Boyle et al., 1991) . Alternatively, multiple spots representing a single phosphorylated section of a protein may appear as a result of partial digestion at a cleavage site that contains two or more adjacent basic residues (Boyle et al., 1991) . The CSF-1 receptor carboxy-terminal tryptic peptide is bordered at the amino-terminus by two neighboring arginine residues and it contains two tyrosine and 14 serine residues (Figure 9e ). Taken together, these observations suggest that the CSF-1 receptor can autophosphorylate on one or more tyrosine residues present within the carboxyterminus. In addition, it is possible that the CSF-1 receptor carboxy-terminus is phosphorylated by serine and threonine speci®c protein kinases.
We have shown that CSF-1 receptor autophosphorylation sites are present within the carboxyterminal tryptic peptide. This peptide contains two tyrosine residues, Tyr 920 and Tyr 973. To distinguish between phosphorylation at these two residues we wanted to generate separate peptides containing either Tyr 920 or Tyr 973. This can be accomplished by digestion with proline-speci®c endopeptidase. Five cleavage sites for proline speci®c endopeptidase are present within the carboxy-terminal tryptic peptide (Figure 9e) .
Wild-type receptors were labeled by autophosphorylation in the presence of g 32 P-ATP, digested with trypsin, and the carboxy-terminal peptide was isolated by immunoprecipitation and analysed by phosphopeptide mapping as described above (Figure 9a ). Partial digestion of this peptide with proline-speci®c endopeptidase resulted in the generation of eight novel phosphopeptides (Figure 9b,d) . The appearance of eight new phosphopeptides is likely to be the result of incomplete digestion of the tryptic peptide at the ®ve potential proline-speci®c endopeptidase cleavage sites (Figure 9e ). In addition, some of these novel peptides could represent phosphorylation state isomers resulting from heterogeneity in serine phosphorylation within the CSF-1 receptor carboxyterminus that occurred before the cells were lysed. Five of these new phosphopeptides disappeared from the peptide map upon mutation of Tyr 973 to Phe (Figure 9c,d) . This result provides direct evidence that Tyr 973, present four residues from the CSF-1 receptor carboxyterminus, is a substrate for receptor autophosphorylation.
Discussion
Previous work has implicated c-Cbl as a mediator and negative regulator of CSF-1 receptor signaling. c-Cbl binds to the CSF-1 receptor, becomes tyrosine phosphorylated, and associates with other proteins in response to CSF-1 (Wang et al., 1996 . In the absence of c-Cbl, macrophages proliferate more rapidly, grow into denser colonies, and show reduced CSF-1 receptor multi-ubiquitination (Lee et al., 1999) . Exactly how c-Cbl and the CSF-1 receptor interact remains poorly understood. Here we have shown that c-Cbl binds directly to the CSF-1 receptor and that this interaction depends on receptor autophosphorylation. Mutation of Tyr 973 blocks binding of the c-Cbl TKB domain to the receptor in vivo and in vitro. Phosphopeptide mapping experiments con®rmed that the CSF-1 receptor can autophosphorylate at its carboxy-terminus. Carboxy-terminal peptides were isolated from a tryptic peptide mixture by immunoprecipitation, partially digested with proline speci®c endopeptidase and resolved in two dimensions on a TLC plate. Phosphopeptides were visualized by autoradiography. (d) A schematic representation of the phosphopeptide map obtained after partial digestion of the wild-type CSF-1 receptor carboxyterminal tryptic peptides with proline speci®c endopeptidase. * Tryptic phosphopeptides derived from the carboxy-terminus, * phosphopeptides obtained after digestion of carboxy-terminal tryptic peptides with proline speci®c endopeptidase, * free orthophosphate. Peptides 1 ± 5 disappear from the map upon mutation of Tyr 973. (e) The amino acid sequence of the CSF-1 receptor carboxy-terminal tryptic peptide including two upstream arginine residues is shown (Rothwell and Rohrschneider, 1987) . Cleavage sites for trypsin (following arginine or lysine) and proline-speci®c endopeptidase are indicated by arrows c-Cbl associates with a variety of protein ± tyrosine kinases and, in many cases, this association is mediated by the TKB domain (Joazeiro et al., 1999; Levkowitz et al., 1999; Lupher et al., 1997 Lupher et al., , 1998 Miyake et al., 1999) . Speci®c binding sites have been identi®ed on the EGF receptor at Tyr 1045, on Zap70 at Tyr 292, and on Syk at Tyr 323 . All of these Cbl binding sites are centrally located and are based on a tyrosine residue followed by an acidic amino acid three residues carboxy-terminal to the tyrosine (Table 1) . This is consistent with structural work suggesting that the speci®city of the interaction between the TKB domain and a tyrosine phosphorylation site is determined largely by residues carboxy-terminal to the tyrosine (Meng et al., 1999; Zheng et al., 2000) . In contrast, in vitro phosphopeptide-binding studies suggests that the TKB domain binds to phosphotyrosine in the context of a Asp-Asn/Asp-X-P.Tyr motif, in which the asparagine two residues amino-terminal to the tyrosine is the most important determinant of binding speci®-city . Tyr 973 is present four residues from the carboxy-terminus of the CSF-1 receptor. Instead of an acidic amino acid, a cysteine is present three residues carboxy-terminal to Tyr 973 and, consistent with the peptide selection experiments, an asparagine is present two residues amino-terminal to the tyrosine (Table 1) .
Tyr 721, which is present in the CSF-1 receptor kinase insert region, has previously been identi®ed as a c-Cbl-binding site (Ota et al., 2000) . Our results show some residual binding of the c-Cbl TKB domain to the Phe 973 mutant CSF-1 receptor in vitro. The residual binding seen in our in vitro experiments could be due to binding of the TKB domain to Tyr 721. However, co-immunoprecipitation with the HA-TKB domain was completely abolished by mutation of Tyr 973. This suggests that in vivo the TKB domain binds exclusively to Tyr 973. It is not clear why our results are dierent from those obtained by Ota et al. (2000) . One possible explanation is that the interaction between the CSF-1 receptor and full-length c-Cbl is not mediated by the TKB domain. A second possibility is that the binding speci®city of the TKB domain, when expressed in isolation, is compromised. This, however, is inconsistent with the model that v-Cbl, which is composed of the isolated TKB domain, transforms cells by competing with endogenous c-Cbl for binding sites on activated protein ± tyrosine kinases (Bonita et al., 1997; Miyake et al., 1997) . A third alternative is that, in the TF-1 cells used by Ota and co-workers, Tyr 973 is not phosphorylated and that Cbl associates with the CSF-1 receptor in those cells through an alternative mechanism.
It is well documented that the c-Cbl TKB domain binds directly to phosphorylated tyrosine residues (Joazeiro et al., 1999; Levkowitz et al., 1999) . Our observation that mutation of Tyr 973 blocks c-Cbl binding suggests that this tyrosine residue acts as a CSF-1 receptor autophosphorylation site. In support of this, our phosphopeptide maps of CSF-1 receptors labeled in vitro by autophosphorylation in the presence of g 32 P-ATP contain a phosphopeptide derived from the carboxy-terminus. We have also shown that the CSF-1 receptor can phosphorylate a GST-fusion protein containing the CSF-1 receptor's carboxyterminal 63 amino acids. Tryptic digestion of the CSF-1 receptor yields a peptide containing the carboxy-terminal 60 amino acids. This peptide contains two tyrosine residues and 14 serine residues and is represented by multiple spots on the phosphopeptide map (Figures 8 and 9 ). The appearance of multiple spots representing a single peptide can be caused by separation of phosphorylation state isomers. The presence of phosphorylation state isomers is caused by heterogeneity of phosphorylation at several dierent sites within the same peptide (Boyle et al., 1991) . We have obtained preliminary evidence that indicates that the CSF-1 receptor carboxy-terminus is subject to phosphorylation by serine and threonine speci®c protein kinases in vivo (Wilhelmsen and van der Geer, unpublished observations). This suggests that the appearance of multiple spots on the peptide map representing the CSF-1 receptor carboxy-terminus may result from dierences in the extent of phosphorylation at serine residues that occurred before the receptors were isolated.
To distinguish between phosphorylation at Tyr 920 and Tyr 973 the carboxy-terminal tryptic peptide was digested with proline-speci®c endopeptidase. This resulted in the generation of eight new phosphopeptides. Five of these phosphopeptides represent the Tyr 973 phosphorylation site, since they disappear upon mutation of Tyr 973. The remaining three phosphopeptides most likely represent Tyr 920. Tyr 920 had previously been identi®ed as an autophosphorylation site in v-Fms (Mancini et al., 1997) . Our observations show that Tyr 973 is a bona ®de CSF-1 receptor autophosphorylation site and con®rm that Tyr 920 can be phosphorylated in the wild-type CSF-1 receptor.
There is considerable evidence in the literature implicating Tyr 973 as a negative regulator of CSF-1 Lupher et al., 1997) c-Cbl binds the CSF-1 receptor's carboxy-terminus K Wilhelmsen et al receptor signaling. v-fms, which is constitutively active and induces cellular transformation, diers from the feline CSF-1 receptor by several point mutations and a deletion of the carboxy-terminal 50 amino acids (Woolford et al., 1988) . This suggests that the CSF-1 receptor carboxy-terminus is involved in negative regulation of CSF-1 receptor signaling. This was con®rmed by showing that addition of the CSF-1 receptor carboxy-terminus to v-Fms reduces the transforming activity, while deletion of the carboxyterminus from the CSF-1 receptor produces a partially transforming protein (Browning et al., 1986; Roussel et al., 1987; Woolford et al., 1988) . Mutation of Tyr 973 was shown to be as eective as deletion of the carboxyterminus in increasing the transforming potential of the CSF-1 receptor (Roussel et al., 1987) . Identi®cation of Tyr 973 as a c-Cbl-binding site provides a mechanism for negative regulation of CSF-1 receptor signaling by c-Cbl. Our data suggests that the lack of this c-Cbl binding site in v-Fms contributes to the protein's transforming potential and thus lends further credit to a model in which c-Cbl acts as a negative regulator of CSF-1 receptor signaling (Lee et al., 1999; Wang et al., 1996 Wang et al., , 1999 . Our data are consistent with the following model. CSF-1 receptor activation results in autophosphorylation of several tyrosine residues, including Tyr 973 at its carboxy-terminus. Tyr 973 acts as a binding site for c-Cbl and the interaction with c-Cbl plays a role in negative regulation of CSF-1 receptor signaling. Consequently, deletion of the entire carboxy-terminus or mutation of Tyr 973 prevents the interaction with cCbl and results in prolonged CSF-1 receptor signaling.
Materials and methods

Materials
293T cells were grown in Dulbecco-Vogt-modi®ed Eagle's medium containing 10% calf serum. P388D1 cells (kindly provided by Dr Dennis, UCSD, La Jolla, CA, USA) were grown in Iscoves-modi®ed Dulbecco's medium containing 10% fetal bovine serum. A polyclonal anti-CSF-1 receptor serum was raised against a GST-CSF-1 receptor kinase insert domain fusion protein. In addition, a polyclonal anti-CSF-1 receptor anti-serum raised against the carboxy-terminus (sc-692) was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The anti-phosphotyrosine monoclonal antibody 4G10 was purchased from UBI (Lake Placid, NY, USA). Anti-HA monoclonal antibody 12CA5 and anti-HA polyclonal serum HA.11 were purchased from Covance (Richmond, CA, USA).
Expression of HA-TKB and CSF-1 receptors in 293T cells
The cDNA sequence encoding the c-Cbl TKB (residues 1 ± 357) domain was ampli®ed by PCR using the Advantage-HF 2 PCR kit from Clontech (Palo Alto, CA, USA). Primers included restriction sites, and the cDNA encoding the TKB domain was cloned into the mammalian expression vector pcDNA3. A Kozak consensus sequence for initiation of protein synthesis and a sequence encoding the HA epitope starting with a methionine were inserted upstream of the cCbl TKB domain. The entire coding region was sequenced to ensure ®delity. A glycine to glutamic acid mutation at position 306 in the c-Cbl TKB domain was introduced using the Transformer Site-Directed Mutagenesis Kit purchased from Clontech (Palo Alto, CA, USA), according to the manufacturer's speci®cations.
Wild-type and mutant CSF-1 receptor cDNAs were cloned into pcDNA3. Stop codons were introduced at positions 927, 937, 947, 957 and 967, and tyrosine 973 was changed to phenylalanine using the Transformer Site-Directed Mutatgenesis Kit (Clontech, Palo Alto, CA, USA). Mutant cDNAs were sequenced to ensure ®delity.
293T cells were grown on 10 cm tissue culture dishes coated with polylysine and transfected at 30% con¯uency with 2 mg of pcDNA3 CSF-1 receptor and 2 mg pcDNA3 HA-TKB. Transfections were carried out using Lipofectin and Optimem purchased from Gibco BRL (Gaithersburg, MD, USA). Cells were lysed 96 h after transfection.
GST fusion protein
A construct for expression of a GST-TKB domain fusion protein was generated by cloning a PCR fragment containing c-Cbl residues 1 ± 357 into pGEX-4T-2. Expression of fusion proteins was induced by 100 mM IPTG for 3.5 h at 378C. Bacteria were lysed by sonication in 10 mM Tris/Cl pH 7.4 and 150 mM NaCl (TBS). Triton X-100 was added to a ®nal concentration of 1%, insoluble material was removed by centrifugation for 10 min at 10 000 g at 48C and fusion proteins were puri®ed by binding to glutathione-agarose. Glutathione-agarose beads were collected by centrifugation and washed three times with TBS. Fusion proteins were stored bound to beads at 48C in TBS containing 0.02% sodium azide.
Immunoprecipitation and GST fusion-protein pulldown experiments
Cells were grown to con¯uency on 10 cm tissue culture dishes, rinsed twice with cold TBS and lysed in 1 ml 50 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl 2 , 1 mM EGTA, 100 mM NaF, 10 mM sodium pyrophosphate, 500 mM sodium vanadate, 10 mg/ml aprotinin and 10 mg/ml leupeptin (PLC-lysis buer) per 10 cm tissue culture dish. Lysates were cleared by centrifugation at 10 000 r.p.m. in a microfuge at 48C. CSF-1 receptors were immunoprecipitated by incubation of cell lysates with 5 ml polyclonal anti-CSF-1 receptor kinase insert antiserum for 1 h at 48C, followed by incubation with 100 ml 10% protein A-agarose with rocking for 1 h at 48C. Immunoprecipitates were washed four times with PLC-lysis buer, boiled for 5 min in 62.5 mM Tris/Cl pH 6.8, 10% glycerol, 5% bmercaptoethanol, 5 mM DTT, 2.3% SDS and 0.025% Bromophenol Blue (SDS-sample buer) and resolved by SDS ± PAGE. For anti-HA immunoprecipitates, cell lysates were incubated by rocking for 1.5 h at 48C with 150 ml of a 10% slurry of anti-HA monoclonal antibody coupled to protein A-agarose.
For GST-fusion protein pull-down experiments, lysates were incubated by rocking for 1 h at 48C with 100 ml of a 10% slurry of glutathione-agarose beads containing 1 ± 2 mg of a GST fusion-protein. Agarose beads were collected by centrifugation and washed four times with PLC-lysis buer. Samples were boiled in SDS-sample buer and resolved by SDS ± PAGE.
Immunoblotting
Proteins were transferred to PVDF membranes using a BioRad (Hercules, CA, USA) semi-dry transfer apparatus at 50 mA per gel for 50 min at room temperature. Membranes were blocked for 45 min at room temperature in 10 mM Tris/ Cl pH 7.4, 150 mM NaCl, 0.2% Tween 20 (TBS-T) containing 5% milk and then incubated with a 1 : 200 dilution of a polyclonal CSF-1 receptor antiserum or a 1 : 5000 dilution of polyclonal anti-HA serum in TBS-T with 5% milk for 1 h at room temperature. Blots were washed twice for 10 min in TBS-T and twice for 5 min in TBS. Membranes were then incubated for 30 min with either Protein A-HRP or goat anti-rabbit-HRP diluted 1 : 10 000 in TBS-T and washed as before. Reactive proteins were visualized by ECL purchased from Amersham Pharmacia (Piscataway, NJ, USA). For immunoblotting with the anti-P.Tyr monoclonal 4G10, membranes were blocked with TBS-T containing 5% bovine serum albumin (BSA) followed by an incubation with the anti-serum diluted in TBS-T containing 5% BSA. Washes and detection were done exactly as described for the other anti-sera, except goat anti-mouse-HRP was used as the secondary antibody.
In vitro kinase reactions and phosphopeptide mapping
For in vitro kinase reactions, CSF-1 receptor immunoprecipitates were incubated with 30 ml of kinase buer (20 mM HEPES pH 7.5, 10 mM MnCl 2 , 1 mM DTT) containing 25mCi [g 32 P]-ATP for 30 min at 378C. Reaction mixtures were washed three times in PLC-lysis buer and resolved by SDS ± PAGE. Radiolabeled receptors were localized by autoradiography, isolated from the gel and digested with trypsin (van der Geer et al., 1993) . Phosphopeptides were separated by electrophoresis at pH 1.9 for 35 min at 1 kVolt on an HTLE 7000 electrophoresis apparatus (C.B.S. Scienti®c, Del Mar, CA, USA) and subsequently by chromatography in isobutyric acid buer (van der Geer et al., 1993) . Phosphopeptides were visualized by autoradiography for 1 week at 7808C in the presence of an intensi®er screen. To isolate tryptic phosphopeptides derived from the CSF-1 receptor carboxy-terminus, tryptic digests were incubated with polyclonal antibodies, raised against the carboxy-terminus and immobilized on protein A-agarose beads. The beads were washed several times with 50 mM ammonium bicarbonate at pH 8.0 and phosphopeptides were eluted with pH 1.9 buer and analysed by separation in two dimensions as described above. A GST-CSF-1 receptor carboxy-terminus fusion protein was phosphorylated by incubation with immunoprecipitated CSF-1 receptors in kinase buer containing [g 32 P]-ATP. The fusion protein was resolved from contaminants by SDS ± PAGE and phosphopeptide mapping was performed as described above. Digestion with proline speci®c endopeptidase was carried out for several hours in 50 mM ammonium bicarbonate pH 7.6 at 378C. Following digestion with proline speci®c endopeptidase, peptides were analysed exactly as described for tryptic digests.
